These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 25137169)

  • 1. [An update in drug use during pregnancy: risk classification].
    Gallego Úbeda M; Delgado Téllez de Cepeda L; Campos Fernández de Sevilla Mde L; De Lorenzo Pinto A; Tutau Gómez F
    Farm Hosp; 2014 Jul; 38(4):364-78. PubMed ID: 25137169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
    Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
    Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of prescription medicines in Australian women of child-bearing age.
    Gadzhanova S; Roughead E
    BMC Pharmacol Toxicol; 2015 Dec; 16():33. PubMed ID: 26643036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk classification systems for drug use during pregnancy: are they a reliable source of information?
    Addis A; Sharabi S; Bonati M
    Drug Saf; 2000 Sep; 23(3):245-53. PubMed ID: 11005706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of prescribing in pregnancy using the Irish primary care research network: a pilot study.
    Dillon P; O'Brien KK; McDonnell R; Donnelly-Swift E; Galvin R; Roche A; Cronin K; Walsh DR; Schelten R; Smith S; Fahey T
    BMC Pregnancy Childbirth; 2015 Mar; 15():67. PubMed ID: 25884886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of drug information references emergency medicine clinicians utilize for prescribing in pregnant patients.
    Jellinek SP; Cohen V; Stansfield L; Likourezos A; Sable KN
    Ann Pharmacother; 2010 Mar; 44(3):456-61. PubMed ID: 20164469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs during pregnancy: an issue of risk classification and information to prescribers.
    Sannerstedt R; Lundborg P; Danielsson BR; Kihlström I; Alván G; Prame B; Ridley E
    Drug Saf; 1996 Feb; 14(2):69-77. PubMed ID: 8852521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician characteristics and prescription drug use during pregnancy: a population-based study.
    Weng SS; Chen YH; Lin CC; Keller JJ; Wang IT; Lin HC
    Ann Epidemiol; 2013 Feb; 23(2):54-9. PubMed ID: 23218810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996-2006.
    Artama M; Gissler M; Malm H; Ritvanen A;
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):729-38. PubMed ID: 21626607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescriptions for category D and X drugs during pregnancy in Taiwan: a population-based study.
    Kao LT; Chen YH; Lin HC; Chung SD
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1029-34. PubMed ID: 24578346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
    Yang T; Walker MC; Krewski D; Yang Q; Nimrod C; Garner P; Fraser W; Olatunbosun O; Wen SW
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):270-7. PubMed ID: 18181228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Position Statement from the European Board and College of Obstetrics & Gynaecology (EBCOG) : The use of medicines during pregnancy: call for action.
    Van Calsteren K; Gersak K; Sundseth H; Klingmann I; Dewulf L; Van Assche A; Mahmood T
    Eur J Obstet Gynecol Reprod Biol; 2016 Jun; 201():211-4. PubMed ID: 27132708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women.
    Cleary BJ; Butt H; Strawbridge JD; Gallagher PJ; Fahey T; Murphy DJ
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):408-17. PubMed ID: 20099251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoting appropriate drug use through the application of the Spanish drug-related problem classification system in the primary care setting.
    Gómez MA; Villafaina A; Hernández J; Salgado RM; González MA; Rodríguez J; Martínez de la Concha M; Tarriño A; Gervasini G; Carrillo JA
    Ann Pharmacother; 2009 Feb; 43(2):339-46. PubMed ID: 19193590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Pregnancy and Lactation Labeling Rule (PLLR) on Practicing Dermatologists.
    Beroukhim K; Abrouk M; Farahnik B
    Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study.
    Daud AN; Bergman JE; Bakker MK; Wang H; Kerstjens-Frederikse WS; de Walle HE; Groen H; Bos JH; Hak E; Wilffert B
    Drug Saf; 2015 Jul; 38(7):651-9. PubMed ID: 26017034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member.
    Krenzelok EP
    Clin Toxicol (Phila); 2009 Sep; 47(8):784-9. PubMed ID: 19735211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary care physicians' use of FDA-approved prescription drug labels.
    Sullivan HW; O'Donoghue AC; Aikin KJ
    J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The correct usage of medicines, a safety concept].
    Rouault M; Hoffman C
    Rev Infirm; 2016 May; 221():16-9. PubMed ID: 27155270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.